Neurocrine Biosciences is joining the M&A bonanza with a $2.9 billion takeover of profitable rare disease drugmaker Soleno Therapeutics. Neurocrine will pay $53 per share,

It’s no secret that cancer drug development is full of bandwagons. Companies see a promising target, and crowd around it (see PD-1xVEGF or HER2 for

Syneron Bio said it raised a Series B round worth $150 million, which it will use to back the development of a drug class that’s

Welcome back to Endpoints Weekly! They say March comes in like a lion and out like a lamb, but two pharma giants made a roar

Trump signs his pharma tariffs executive order, which won’t affect most large pharma groups but could deal a hefty blow to smaller companies.